NCT00194467View on ClinicalTrials.gov

Suppression of Oral HHV8 Shedding With Valganciclovir

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

March 31, 2005

Study Completion Date

March 31, 2005

Conditions
Human Herpesvirus 8
Interventions
DRUG

valganciclovir

900 mg once a day for 8 weeks

DRUG

placebo

matching placebo, once a day for 8 weeks

Trial Locations (1)

98122

University of Washington Virology Research Clinic, Seattle

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

University of Washington

OTHER

NCT00194467 - Suppression of Oral HHV8 Shedding With Valganciclovir | Biotech Hunter | Biotech Hunter